A Comparative Study of Immunotherapy as Second-Line Treatment and beyond in Patients with Advanced Non-Small-Cell Lung Carcinoma
Open Access
- 11 March 2021
- journal article
- research article
- Published by Taylor & Francis in Lung Cancer Management
- Vol. 10 (3) , LMT47
Abstract
Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy. Materials...Keywords
Funding Information
- provision of material
This publication has 18 references indexed in Scilit:
- PD-L1 Expression in Lung CancerJournal of Thoracic Oncology, 2016
- Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancersHuman Vaccines & Immunotherapeutics, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Cancer immunotherapy: harnessing the immune system to battle cancerJournal of Clinical Investigation, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Treatment of advanced non small cell lung cancer2011
- CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.Journal of Experimental Medicine, 1995
- CTLA-4 can function as a negative regulator of T cell activationImmunity, 1994